MabVax Therapeutics Holdings News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

03.05.18	AudioEye Selected by International Luxury Brand Canali for Web Accessibility (PR Newswire)
15.03.18	MabVax Therapeutics Announces Acceptance of Three Poster Presentations at the 2018 American Association for Cancer Research (AACR) Annual Meeting (PR Newswire)
06.03.18	MabVax Therapeutics Regains Compliance with NASDAQ's $1.00 Minimum Bid Price Maintenance Requirement (PR Newswire)
28.02.18	MabVax Therapeutics Reports Positive Safety Results from Initial Cohort of MVT-1075 Radioimmunotherapy Phase 1 Trial for the Treatment of Pancreatic, Colon and Lung Cancers (PR Newswire)
19.02.18	Lifshitz & Miller LLP Announces Investigation of A10 Networks, Inc., Aerohive Networks, Inc., Jacksonville Bancorp, Inc., Key Technology, Inc., MabVax Therapeutics Holdings, Inc., MetLife Inc. (PR Newswire)
15.02.18	MabVax Therapeutics Schedules Previously Announced 1-for-3 Reverse Stock Split to Regain Compliance with NASDAQ's $1.00 Minimum Bid Price Maintenance Requirement (PR Newswire)
12.02.18	MabVax Therapeutics Announces Positive Interim Data from Expanded Cohort in Phase 1 Trial Evaluating MVT-5873 in Combination with First-Line Chemotherapy in Pancreatic Cancer (PR Newswire)
07.02.18	MabVax to Present at BIO CEO & Investor Conference (PR Newswire)
06.02.18	MabVax Therapeutics Closes $2.1 Million Private Placement Financing (PR Newswire)
01.02.18	Gum Disease Awareness Month Emphasizes Dangers of the Silent Killer (PR Newswire)
31.01.18	SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of MabVax Therapeutics Holdings, Inc. (MBVX) (PR Newswire)
17.01.18	EIGR Disappoints, EXEL's CELESTIAL Excels, JUNO In CELG's Crosshairs? (RTTNews)
16.01.18	MabVax Therapeutics Holdings, Inc. Provides Business Strategy Update (PR Newswire)
20.12.17	MabVax Therapeutics Announces Completion of Enrollment and Initial Patient Dosing in an Expanded Cohort of the Phase 1 Trial Evaluating MVT-5873 in Combination with First-Line Chemotherapy (PR Newswire)
13.12.17	MabVax Therapeutics Announces Completion of Enrollment and Dosing in Initial Cohort of MVT-1075 Radioimmunotherapy Phase 1 Trial for the Treatment of Pancreatic, Colon and Lung Cancers (PR Newswire)
01.12.17	MabVax Stockholders Approve Proposals at Special Meeting of Stockholders (PR Newswire)
22.11.17	MabVax Announces Adjournment of Special Meeting of Stockholders (PR Newswire)
16.11.17	MabVax Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Listing Requirements (PR Newswire)
13.11.17	MabVax Therapeutics to Present Positive Development Study Results Enabling Manufacturing of Two Radionuclide Products for Phase 1 Clinical Trials at the 2017 AAPS Annual Meeting (PR Newswire)
31.10.17	MabVax Therapeutics Provides Update on the MVT-5873 Phase 1 Clinical Program and Expansion of Preclinical Development Pipeline at the AACR-NCI-EORTC International Conference (PR Newswire)
26.10.17	MabVax Therapeutics to Present Three Posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire)
24.10.17	MabVax Therapeutics Expands Intellectual Property Estate by Filing a New Patent Application on its Fully-Human Antibody Discoveries (PR Newswire)
17.10.17	MabVax Therapeutics Holdings, Inc. Provides Corporate Overview and Business Outlook (PR Newswire)
12.10.17	ARDX Surges After-hours, MBVX Abuzz, TRVN Keeps Its Focus (RTTNews)
11.10.17	MabVax Therapeutics Initiates Patient Enrollment in a Phase 1 Trial for MVT-1075, a New Radioimmunotherapy Treatment for Advanced Pancreatic, Colon and Lung Cancers (PR Newswire)
06.10.17	Bridgepoint Education Schedules Third Quarter 2017 Earnings Conference Call for October 25, 2017 (PR Newswire)
06.10.17	MabVax Stockholders Approve Remaining Proposal at Special Meeting of Stockholders (PR Newswire)
04.10.17	MabVax Stockholders Approve Proposals at Special Meeting of Stockholders (PR Newswire)
03.10.17	Novel Preclinical Studies with MabVax Therapeutics' HuMab-5B1 Antibody and HuMab-GD2 Antibodies Presented at the 2017 World Molecular Imaging Congress (PR Newswire)
12.09.17	MabVax Therapeutics Holdings, Inc. Announces $2.0 Million Registered Direct Offering (PR Newswire)
07.09.17	MabVax Therapeutics Holdings, Inc. to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City (PR Newswire)
06.09.17	MabVax Therapeutics Engages Greenhill & Co. as Advisor for Exploring Strategic Alternatives (PR Newswire)
23.08.17	RARE Disappoints, NSPR Put On Notice, PMD Launches Synthetic Cannabinoids Test (RTTNews)
22.08.17	MabVax Therapeutics Holdings, Inc. Announces the Closing of $1.3 Million Registered Direct Offering and is Engaging an Advisory Bank to Explore Strategic Alternatives (PR Newswire)
14.08.17	MabVax Therapeutics Holdings, Inc. Announces Pricing of Registered Direct Offering (PR Newswire)
24.07.17	MabVax Therapeutics Board of Directors Authorizes the Company to Explore Strategic Alternatives (PR Newswire)
27.06.17	MabVax Therapeutics Commences Patient Dosing in MVT-1075 Radioimmunotherapy Phase 1 Clinical Trial for the Treatment of Pancreatic, Colon and Lung Cancers (PR Newswire)
14.06.17	MabVax Therapeutics Reports Positive Phase 1 Results for MVT-2163 ImmunoPET Imaging Agent (PR Newswire)
07.06.17	MabVax Therapeutics ImmunoPET Imaging Agent MVT-2163 to be Featured in Two Presentations at the 2017 SNMMI Annual Meeting (PR Newswire)
05.06.17	MabVax Therapeutics Phase I Trial Results of Antibody Therapy MVT-5873 for the Treatment of Advanced Pancreatic Cancer Presented at the 2017 ASCO Annual Meeting (PR Newswire)
25.05.17	MabVax Therapeutics to Present Phase I Clinical Trial Results of MVT-5873 for the Treatment of Advanced Pancreatic Cancer in Poster Presentation at the 2017 ASCO Annual Meeting (PR Newswire)
24.05.17	MabVax Therapeutics Reports First Quarter 2017 Operational and Financial Results (PR Newswire)
22.05.17	MabVax Therapeutics Announces the Closing of its $4.1 Million Public Offering (PR Newswire)
16.05.17	AKBA Abuzz, ANTH On Track For RESULT, IMUC Faces Cash Crunch, IONS Falls (RTTNews)
16.05.17	MabVax Therapeutics Announces $4.1 Million Public Offering (PR Newswire)
08.05.17	COEUR, PROJECT Womens Partner To Launch New Lifestyle Platform During Market In Las Vegas (PR Newswire)
05.04.17	MabVax Therapeutics Presents Two Posters at the American Association for Cancer Research (AACR) Annual Meeting on a Novel Radioimmunotherapy Treatment for Pancreatic Cancer (PR Newswire)
23.02.17	MabVax Therapeutics Announces FDA Authorization to Proceed with MVT-1075 in a Phase I Clinical Trial for the Treatment of Pancreatic Cancer (PR Newswire)
13.02.17	MabVax Therapeutics Studies Lead Investigational Drug MVT-5873 with Halozyme PEGPH20 (PR Newswire)
05.12.16	MabVax Therapeutics Expands Phase I Clinical Trial Investigation for Patients with Pancreatic Cancer to Include HonorHealth Research Institute (PR Newswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’350.00	1.12 %	K V
CieFinRichemont	165.75	1.04 %	K V
Alcon	78.70	0.92 %	K V
Lonza Grp	567.00	0.67 %	K V
Logitech Intl	80.14	0.53 %	K V
UBS Group	31.65	-0.31 %	K V
Kuehne+Nagel Int	205.80	-0.44 %	K V
Geberit	504.00	-0.47 %	K V
Holcim	86.86	-0.64 %	K V
Sika	224.90	-1.01 %	K V